Catalog No.
DHC33102
Expression system
Mammalian Cells
Species reactivity
Human
Isotype
Fusion - [ACVR2A (activin A receptor type 2A, ActR-II, ActRIIA)]2 - IGHG1 Fc (Fragment constant)
Target
EDF, Erythroid differentiation protein, Activin beta-A chain, INHBA, Inhibin beta A chain
Concentration
1.05 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08476
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ACE-011, ACTRIIA-Fc, MK 7962, MK-7962, MK7962, Sotatercept (USAN/INN), SOTATERCEPT-CSRK, WINREVAIR, CAS: 1001080-50-7
Clone ID
Sotatercept
Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control., PMID:40481031
The Potential Impact of Sotatercept on Long-Term Disability in Commercially Insured Patients with Pulmonary Arterial Hypertension in the United States: An Exercise in Actuarial Modeling., PMID:40445230
Sotatercept and the Clinical Transformation of Pulmonary Arterial Hypertension., PMID:40435469
Sotatercept: A Crosstalk Between Pathways and Activities in the Pulmonary Circulation and Blood., PMID:40429991
ERJ Podcast May 2025: Efficacy and safety of the activin signalling inhibitor sotatercept., PMID:40425258
Treatment of pulmonary hypertension after seven world symposia., PMID:40405724
Sotatercept in pulmonary arterial hypertension., PMID:40382242
Therapeutic targets for pulmonary arterial hypertension: insights into the emerging landscape., PMID:40368635
Drugs targeting novel pathways in pulmonary arterial hypertension., PMID:40341051
Activin-A Regulates Bone Morphogenetic Protein Signaling in Pulmonary Endothelial Cells Without Affecting Bone Morphogenetic Protein Type-II Receptor Expression., PMID:40330556
Updates on Pulmonary Hypertension., PMID:40322494
Severe Hypoxemia and Pulmonary Capillary Dilatations in PAH Patients Treated with Sotatercept., PMID:40315146
Simplifying Sotatercept in Pulmonary Arterial Hypertension: Genetic Context Meets Treatment Response., PMID:40315138
Development of New Intrapulmonary Shunts in Pulmonary Arterial Hypertension Treated with Sotatercept., PMID:40315133
Withdrawal of prostacyclin pathway therapies after initiation of sotatercept treatment in patients with pulmonary arterial hypertension., PMID:40268508
Sotatercept as add-on therapy for advanced PAH., PMID:40263579
Exploring the Economic Burden of Pulmonary Arterial Hypertension and Its Relation to Disease Severity and Treatment Escalation: A Systematic Literature Review., PMID:40244370
Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs., PMID:40192154
Clinical trial landscape for pulmonary arterial hypertension targeted therapy: Beyond vasodilators., PMID:40175270
Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death., PMID:40167274
Sotatercept Use in a Patient with Pulmonary Arterial Hypertension Undergoing Lung Transplantation., PMID:40144721
Management of Pulmonary Arterial Hypertension: Current Strategies and Future Prospects., PMID:40141775
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)., PMID:40035659
A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma., PMID:40033065
Sotatercept: A First-In-Class Activin Signaling Inhibitor for Pulmonary Arterial Hypertension., PMID:39995630
New therapies in pulmonary arterial hypertension: Recent insights., PMID:39991439
Revisiting treatment of pulmonary arterial hypertension in the current era: a Greek scientific document., PMID:39983868
A Long-Term Follow-Up Study of Sotatercept for Treatment of Pulmonary Arterial Hypertension: Interim Results of SOTERIA., PMID:39978862
Ineffectiveness of Sotatercept Therapy in a Patient With Heritable Pulmonary Arterial Hypertension Associated With a Previously Unreported Missense Variant in GDF2, the Gene for Bone Morphogenic Protein-9., PMID:39939060
Exploring Novel Therapeutics for Pulmonary Arterial Hypertension., PMID:39894550
Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies., PMID:39884760
Shifting Paradigms in the Management of Pulmonary Hypertension., PMID:39872419
The Drug Update: Recent drug approvals, winter 2025 edition., PMID:39844320
Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies., PMID:39829438
Sotatercept in pulmonary hypertension and beyond., PMID:39825683
[Pneumology : what's new in 2024]., PMID:39812291
Sotatercept: A New Era in Pulmonary Arterial Hypertension., PMID:39773755
Emerging therapies and new directions in the treatment of pulmonary arterial hypertension., PMID:39743894
Sotatercept in PAH: A promising pathway while awaiting long-term outcomes., PMID:39736424
Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling Analyses of Sotatercept in Healthy Participants and Patients with Pulmonary Arterial Hypertension., PMID:39668469
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR., PMID:39645016
Sotatercept: New drug on the horizon of pulmonary hypertension., PMID:39571875
Risk assessment models and survival in pulmonary arterial hypertension: a SPAHR analysis., PMID:39536922
Perspectives on Sotatercept in Pulmonary Arterial Hypertension., PMID:39518603
Sotatercept: The First FDA-Approved Activin A Receptor IIA Inhibitor Used in the Management of Pulmonary Arterial Hypertension., PMID:39466552
A Belgian consensus on sotatercept for the treatment of pulmonary arterial hypertension., PMID:39377139
A new day has come: Sotatercept for the treatment of pulmonary arterial hypertension., PMID:39369970
For research use only. Not for human or drug use.
